Faculty profile

Versha Banerji

ResearcherImmunologyUniversity of Manitoba

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Manitoba directory, so their courses and email address may be missing. Find their university profile.

Versha Banerji

Researcher

Immunology

Health Sciences

University of Manitoba

Winnipeg, Manitoba, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
38 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

114

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Latest papers

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Blood · 2026
Reduction-Free Thermolysin Digestion Enables Absolute Protein Quantitation in Plasma in 35 min from Sample to Result.
Journal of proteome research · 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Journal of geriatric oncology · 2026

All 71 publications

Latest funding

38th Annual Canadian Society of Immunology (CSI) 2026 meeting
CIHR · 2025 · Principal investigator
$20,000
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
CIHR · 2020 · Co-investigator
$100,000
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
CIHR · 2020 · Co-investigator
$100,000

All 5 grants and awards

71 publications.

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Zent CS, Tiacci E, Kreitman RJ, Tadmor T, Tallman MS, Wörmann B, Andritsos LA, Arons E, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call TG, Dearden C, Demeter J, Dietrich S, El-Sharkawi D, Fagarasanu A, Falini B, Forconi F, Gerrie AS, Gladstone DE, Gozzetti A, Hampel PJ, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kipps TJ, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tam CS, Troussard X, Zenz T, Zinzani PL, Grever MR

Blood2026

DOI: 10.1182/blood.2025032757 PMID: 41980020

Reduction-Free Thermolysin Digestion Enables Absolute Protein Quantitation in Plasma in 35 min from Sample to Result.

Jiang X, Lao Y, Johnston JB, Banerji V, Zahedi RP

Journal of proteome research2026

DOI: 10.1021/acs.jproteome.6c00197 PMID: 42113895

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Ghia P, Rossi D, Ferrant E, de la Cruz Vicente F, Maruyama D, Banerji V, Cobb P, Namburi S, Greil R, Sharman JP, Hess LM, Payakachat N, Bhandari NR, Ruppert AS, Wang D, Abada P, Loubert A, Creel K, Qiao C, Han Y, Hill M, Leow CC, Coombs CC, Barr PM

Journal of geriatric oncology2026

DOI: 10.1016/j.jgo.2026.103024 PMID: 42308688

Adapting high-resolution respirometry for adherent brain endothelial cells reveals stable and reproducible mitochondrial respiration.

Jain C, Grewal A, Kuzmychova H, Mukherjee R, Chawla U, Banerji V, Martell E, Sharif T

Biochemical and biophysical research communications2026

DOI: 10.1016/j.bbrc.2026.153727 PMID: 41962410

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Senthil H, Streilein S, Whiteside T, Minuk L, Landego I, Kotb R, Menard C, Kansara R, Moltzan CJ, Johnston JB, Skrabek P, Yang L, Geirnaert M, Banerji V

Haematologica2026Senior author

DOI: 10.3324/haematol.2025.288780 PMID: 41063693

Extracellular lactate reprograms mitochondrial metabolism and NAD+/NADH redox balance in blood-brain barrier endothelial cells via an LDHB-MPC-NAD+ axis.

Jain C, Kuzmychova H, Grewal A, Chawla U, Mukherjee R, Banerji V, Anderson CM, Martell E, Sharif T

Free radical biology & medicine2026

DOI: 10.1016/j.freeradbiomed.2026.05.335 PMID: 42217683

Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis.

van de Wetering G, Owen C, Banerji V, Gosselin A, Kamdar S, Roc NP, Bakker L, Ratnaparkhi G, Barakat S, Vicente C, Manzoor BS

PharmacoEconomics - open2026

DOI: 10.1007/s41669-025-00610-1 PMID: 41203994

Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System.

Lemieux C, Phua CW, Robinson KS, Owen C, Banerji V

Current oncology (Toronto, Ont.)2025Senior author

DOI: 10.3390/curroncol32100543 PMID: 41149463

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA

Blood2025

DOI: 10.1182/blood.2024024476 PMID: 40198878

A Scoping Review Mapping Trans* and Gender Diverse People's Representation in Cancer Research.

Stirling M, Bourque MA, Hunter M, Queenan J, Ludwig C, Ristock J, Harrison L, Ross-White A, Nickel NC, Schultz A, Banerji V, Gahagan J, Mahar A

Cancer medicine2025

DOI: 10.1002/cam4.70774 PMID: 40761093

Something wrong or missing on this profile? Suggest a correction

Versha Banerji

Research

Latest papers

Latest funding

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Reduction-Free Thermolysin Digestion Enables Absolute Protein Quantitation in Plasma in 35 min from Sample to Result.

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Adapting high-resolution respirometry for adherent brain endothelial cells reveals stable and reproducible mitochondrial respiration.

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.

Extracellular lactate reprograms mitochondrial metabolism and NAD+/NADH redox balance in blood-brain barrier endothelial cells via an LDHB-MPC-NAD+ axis.

Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis.

Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System.

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

A Scoping Review Mapping Trans* and Gender Diverse People's Representation in Cancer Research.

38th Annual Canadian Society of Immunology (CSI) 2026 meeting

Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Linking Inflammation and Metabolism with Frailty in Chronic Cancer

Chronic Lymphocytic Leukemia - New Discoveries and Options for Patients.

Frequent collaborators

Sachin Katyal

Tanveer Sharif

Lisa Chodirker

Brian Leber

Aaron Marshall

Mitchell Sabloff

Christiaan Righolt

Sheila Singh

Lee Mozessohn

Shabbir Alibhai

Annette Schultz

Chantal Guillemette

Francis Lin

Annette Schultz

Jean-Eric Ghia

Kathleen Decker

Christine Doucette

Sudeep Shivakumar

Alyson Mahar

John Kuruvilla